We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PSMT:NASDAQPriceSmart, Inc. Analysis

Data as of 2026-06-30 - not real-time

$195.75

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

PriceSmart’s stock is trading near its 52‑week high of $197.72, comfortably above the 20‑day SMA of $180.71 and the 50‑day SMA of $168.60, confirming a strong upward bias. The 200‑day SMA sits at $142.54, further underscoring the long‑term bullish trend. Momentum indicators are extreme, with the RSI perched at 79.6, signaling an overbought condition that could invite short‑term profit‑taking. The MACD remains bullish, as the line sits above the signal and the histogram is positive, while volume is on an increasing trajectory. The stock’s beta of 0.67 indicates lower systematic risk than the market, and the 30‑day volatility of roughly 21% reflects heightened short‑term price swings. These technical signals collectively suggest strong current demand but also warn of potential near‑term pullbacks.
Fundamentally, the company generates $5.5 bn in revenue with 9.7% growth, yet profitability is modest (gross margin 17.6%, operating margin 5.1%). The trailing PE of 38.6 and forward PE of 27.8 are well above the sector average, and the DCF‑derived fair value of $44.68 is dramatically lower than the current price of $195.75, indicating substantial overvaluation. Despite this, the dividend yield of 0.72% and a payout ratio of roughly 26% point to a sustainable payout policy. The balance sheet is relatively clean, with cash roughly equal to debt and a debt‑to‑equity of 23.6%, supporting financial stability. Geographic exposure across the U.S., Central America, the Caribbean, and Colombia adds a medium‑level geographic risk, but the consumer‑defensive sector generally buffers earnings. Overall, the stock’s upside appears limited while downside risk remains tied to valuation correction and overbought momentum.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicates overbought conditions
  • Bullish MACD supports momentum
  • Elevated short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • High trailing PE relative to sector
  • Modest earnings margins limiting upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustainable dividend payout
  • Low leverage and solid cash position
  • Defensive consumer sector providing earnings resilience

Key Metrics & Analysis

Financial Health

Revenue Growth9.70%
Profit Margin2.82%
P/E Ratio38.6
ROE12.45%
ROA6.95%
Debt/Equity23.64
P/B Ratio4.4
Op. Cash Flow$268.2M
Free Cash Flow$68.9M

Technical Analysis

TrendBullish
RSI79.6
Support$163.60
Resistance$197.72
MA 20$180.71
MA 50$168.60
MA 200$142.54
MACDBullish
VolumeIncreasing
Fear & Greed Index90.13

Valuation

Fair Value$44.68
Target Price$153.33
Upside/Downside-21.67%
GradeOvervalued
TypeGrowth
Dividend Yield0.72%

Risk Assessment

Beta0.67
Volatility21.29%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.